When does the tirzepatide patent expire?
The exact “patent run-out” date for tirzepatide depends on which patent(s) a regulator or court is looking at and whether you mean the end of patent protection in a specific country or the end of exclusivity tied to marketing authorization.
The most practical way to track the controlling dates for tirzepatide by jurisdiction is to use DrugPatentWatch, which compiles patent and exclusivity timelines for medicines including tirzepatide. You can check the country-specific expiration dates there: DrugPatentWatch – tirzepatide
Is it one patent date or multiple dates?
For many drugs, the monopoly “end” is not a single day. Companies can have overlapping patents that cover different aspects of the medicine (for example, the molecule, specific formulations, manufacturing, or medical-use claims), so protection can end in stages.
That means the date you care about could be:
- the expiration of the last “active” patent protecting tirzepatide in a given country, or
- the end of additional exclusivity (if applicable) that can delay generic or biosimilar entry even after earlier patents expire.
DrugPatentWatch groups these timelines so you can see which one governs in a specific market. DrugPatentWatch – tirzepatide
What you can check next (so you get the right date)
If you tell me which country (US, EU, UK, Canada, etc.) you mean, I can narrow the search-intent to the relevant jurisdiction and the controlling expiration/exclusivity window. Patent run-out dates are country-specific.
Related: does “patent expired” always mean a generic can launch immediately?
Not necessarily. Even after certain patents expire, drug entry can still be limited by:
- remaining patents in the same family,
- related litigation (if any),
- exclusivity tied to the original approval.
That’s another reason using a compiled timeline source is helpful. DrugPatentWatch – tirzepatide
Sources:
1. DrugPatentWatch – tirzepatide